Introduction
Among patients with angina, the absence of 'significant' coronary artery disease (CAD)-i.e. absence of > _50% diameter stenosis in any major epicardial vessel-is a relatively common finding, being reported in 20-30% of patients undergoing coronary angiography 1, 2 regardless of the previous documentation of myocardial ischaemia. 2, 3 This condition, often defined as 'angina without obstructive CAD' and sometimes referred to as 'angina with normal coronary arteries', has controversial prognostic implications. Many studies claim that the condition is associated with a high incidence of adverse events, while others have only documented impaired quality of life. Published studies suffer from heterogeneous inclusion criteria, regarding both the qualification of 'angina' (i.e. typical or atypical angina), the inclusion of symptomatic or asymptomatic subjects, the definition of 'absence of obstructive CAD' (i.e. 'less-than-obstructive CAD' or normal coronary arteries). Such limitation affected also two recent meta-analysis, 4 ,5 both including an extremely heterogeneous population, ranging from asymptomatic subjects to patients admitted for an acute coronary syndrome (ACS). We, therefore, primarily aimed at assessing long-term clinical outcomes in the follow-up of symptomatic, stable patients with angina (or anginal equivalent) without obstructive CAD, through a rigorous systematic review and meta-analysis of observational studies. Our second aim was to identify differences in the incidences of adverse cardiovascular events among patient subgroups.
Methods
We planned, conducted, and reported the current systematic review and meta-analysis in accordance with currently available statements for design, analysis, and reporting of meta-analyses of randomized and observational studies. 6 We searched PubMed, the Cochrane Library (www.
cochranelibrary.com), and the Embase (through Ovid SP) databases, as well as the National Institutes of Health (NIH) Clinical Trials Registry (www.clinicaltrials.gov) from 1980 to 2017, using the following key terms: 'microvascular angina' OR 'vasospastic angina' OR 'Prinzmetal angina' OR 'syndrome X' OR 'normal coronar*' OR 'no obstructive' OR 'nonobstructive' OR 'non-obstructive' OR 'non-obstructive' AND prognosis OR event OR outcome* OR Death OR mortality OR endpoint OR endpoint. We also checked the reference list of all identified articles for additional relevant studies, including hand-searching reviews and previous meta-analyses. This methodological approach has been previously validated in our hands. 7, 8 Two authors (F.R. and F.F.) screened the articles according to pre-specified inclusion and exclusion criteria, and independently extracted the data. We resolved disagreements by consensus with a third investigator (M.Z. ) . We considered studies eligible if they reported adverse cardiovascular events in symptomatic individuals with stable angina (or angina-like chest pain, or anginal equivalents) or vasospastic angina and 'normal' coronary arteries or non-obstructive CAD at either invasive coronary angiography (ICA) or at coronary computerized tomography angiography (CCTA). We defined non-obstructive CAD as the absence of stenosis > _50% in at least one epicardial coronary artery, this being the most commonly used cut-off point. We excluded from the analysis studies meeting the following criteria: (i) non-English language; (ii) reviews, meta-analyses, editorials, abstracts; (iii) diagnostic accuracy studies without clinical outcomes; (iv) studies with follow-up duration <12 months; (v) studies including asymptomatic patients (neither angina nor angina-equivalent symptoms); (vi) studies enrolling patients with ACSs, the Takotsubo syndrome, other cardiomyopathies, end-stage chronic kidney disease, and heart-transplant recipients ( Figure 1) . In case of duplicates, we included only the study with the larger sample size. We used a standardized data extraction form to collect publication year, follow-up duration, sample size, clinical characteristics and main outcomes. Three selected studies 2,9,10 reported events in odds and relative risk ratios, and in this case we retrieved the crude event number by direct requests to the corresponding authors.
Outcome measures
The primary outcome was the composite pooled incidence of all-cause death and non-fatal myocardial infarction (MI). Secondary outcomes were the single occurrence of all-cause death, non-fatal MI, and cardiovascular hospitalization, defined as hospitalization for congestive heart failure, cardiac arrhythmias, ACSs, or any other manifestation of ischaemic heart disease, according to the International Classification of Diseases-9 criteria. We also analysed the incidences of angina recurrence and repeated coronary angiography.
Statistical analysis
For each included study, we calculated incidence with its 95% confidence interval (CI) for every pre-defined outcome. We computed incidences as the ratios between the number of events and the number of person-time (years) at risk, in order to account for the heterogeneity of follow-up duration across different studies. Confidence intervals were calculated approximating the Poisson distribution to a normal distribution. According to this method, the standard error (SE) of the incidence is computed as the square root of the total number of events (n). Then CIs around the observed rate are calculated as the incidence ± k Â SE, where k is a constant equal to 1.96 for the 95% CIs.
We used DerSimonian and Laird random-effects models to estimate summary pooled incidence of pre-specified outcomes and for sensitivity analyses. We graphically represent pooled results in forest plots, with point estimates of the effect size and 95% CIs for each trial and for the studies overall, being the area of squares proportional to each study weight. We considered a two-sided P-value <0.05 as statistically significant.
We performed a Jackknife (leave-one-out) sensitivity analysis for each outcome in order to evaluate the robustness of the results and the impact of each single study on the summary estimate of effect: we recalculated pooled estimates multiple times, using a random-effects model, each time with the removal of a single study from the original group. We also performed a sensitivity analysis stratified by sample size to exclude the possibility of overestimating the incidence of adverse cardiovascular events due to the inclusion of small studies, here defined as those with a sample size <50. We assessed the likelihood of publication bias using funnel plots displaying incidences with 95% CI of individual studies for each endpoint of interest, and evaluated it by the Egger's regression asymmetry test. We also performed the non-parametric 'trim-and-fill' procedure, adjusting for funnel plot asymmetry by computing hypothetical missing studies. We formally assessed statistical heterogeneity by a v 2 test, and quantified it using the inconsistency index (I 2 ) statistic, defined as the percentage of the observed between-trial variability that is due to heterogeneity rather than chance; I 2 ranges from 0 to 100% and heterogeneity is considered substantial for an I 2 > _50%. We a priori expected a high degree of heterogeneity across individual studies, and therefore planned subgroup analyses according to: (i) definition of 'normal' coronary arteries (less-than-obstructive CAD, i.e. <50% coronary stenosis, vs. 'entirely smooth' coronary arteries, i.e. absence of any angiographically appreciable atherosclerosis); (ii) presence or absence of documentation of myocardial ischaemia (here including also documented coronary dysfunction) as a prerequisite inclusion criterion in the various studies; (iii) the clinical presentation: typical angina, vasospastic angina, and 'undefined' angina type, in this latter definition referring to studies not qualifying the typicality of angina, or including also patients with atypical angina or angina equivalents, and finally, (iv) the diagnostic modality to assess CAD, either ICA or CCTA. We, then, performed subgroup analyses by computing the effect within each subgroup and then comparing the summary effects across subgroup, as previously reported. 11 We also performed simple meta-regression analyses by pre-specified variables, including sex, age, and other traditional risk factors for CAD, such as diabetes, hypertension, dyslipidaemia, smoking habits, and obesity. We performed all analyses and drew graphs using the Review Manager (RevMan version 5.3 
Primary outcome
Of the 54 studies included ( Figure 1 and Figure S1 ). Visual inspection of the funnel plot revealed a very sparse distribution of data, with some asymmetry caused by the absence of studies on the lower left corner. This suggested the possibility that smaller studies with 'neutral' results were not published (Egger's test P = 0.09). The non-parametric 'trim-and-fill' procedure imputed nine hypothetically 'missing' studies, and we calculated that the addition of these to the pooled estimates would lead to an adjusted incidence of 0.85 (95% CI 0.62-1.08)/100 person-years ( Figure 3) . We documented a considerable heterogeneity among studies. Hence, we performed subgroup analyses and meta-regressions to explore sources of clinical and statistical heterogeneities among studies. Univariable meta-regression analyses showed a significant association between the primary outcome incidence and prevalent dyslipidaemia (P = 0.011), diabetes (P = 0.049) and hypertension (P = 0.038) (Figure 4 ), but failed to reveal any significant association with other cardiovascular risk factors (namely age, sex, smoking history, obesity, and body mass index).
Of note, studies including patients with less-than-obstructive CAD showed a significantly higher incidence of the primary outcome Ostorm et al. Note: in the 'Test for myocardial ischaemia' column percentages refer to the proportion of patients in which a stress test was performed. This is specified exclusively for studies in which myocardial ischaemia was not considered as a pre-requisite inclusion criteria (see the previous column (Supplementary material online, Figure S2 ). Primary outcome estimates were not different (P = 0.95) by stratifying studies according to the diagnostic modality to detect CAD: Figure 2 Primary outcome of this study: combined incidence of all-cause death and myocardial infarction. Forest plot showing individual and overall estimated incidence with 95% confidence interval (95% CI) for the combined primary outcome. The vertical red line indicates the pooled averaged incidence rate estimate and the blue diamond represents the overall estimated incidence with 95% confidence interval in a random-effects model. Black squares indicate weighted point estimates of incidence for each single study, with grey horizontal lines indicating 95% confidence interval. I 
Secondary outcomes
All-cause mortality Data on all-cause mortality were available in all the 54 studies identified, accounting for an overall population of 35 039 patients with a median follow-up of 5 (IQR 3-7) years. The estimated pooled allcause mortality was 0.65 (95% CI 0.50-0.79)/100 person-years ( Figure 6) . As for the primary outcome, the results were consistent in the Jackknife sensitivity analysis and in the sensitivity analysis stratified by sample size. No indication of publication bias was found (Supplementary material online, Figure S3 , Egger's test, P = 0.310). Again, heterogeneity among studies was considerable (I 2 = 88%, P < 0.01). Apart from dyslipidaemia (P = 0.02), meta-regression analysis did not reveal any significant effect mediated by other covariates. In subgroup analyses, the presence of non-obstructive CAD was associated with significantly higher all-cause mortality [0. 74 
Non-fatal myocardial infarction
The incidence of non-fatal MI was reported in 49 studies, accounting for a total pooled population of 29 335 with a median follow-up of 5 (IQR 3-7) years. The pooled MI incidence was 0.32 (95% CI 0.24-0.39)/100 person-years, with a substantial heterogeneity among studies (I 2 = 74%, P < 0.01) (Figure 7) . Results were consistent in the Jackknife sensitivity analysis as well as in the sensitivity analysis stratified for sample size. We here found no publication bias. Univariable meta-regression analyses revealed a significant relationship of non-fatal MI with hypertension and-of borderline significance-with diabetes (P = 0.02 and P = 0.05, respectively). Among the other pre-specified subgroup analyses, there were no other significant associations.
Cardiovascular hospitalization
Twenty-four studies provided data about cardiovascular hospitalization, for a total population of 13 067 patients and with a median follow-up of 5.2 (IQR 3-7) years. The pooled incidence of cardiovascular hospitalization was 2.62 (95% CI 2.14-3.09)/100 person-years, with a considerable heterogeneity among studies (I 2 = 92%, P < 0.01) (Supplementary material online, Figure S4 ). Results were consistent throughout sensitivity and subgroup analyses. We found no 
Discussion
In this meta-analysis, we aimed at assessing clinical outcomes during the long-term follow-up of a large population of symptomatic patients suffering from angina pectoris but without obstructive CAD, providing much needed information on a topic of controversy. This analysis provides a foundation for further discussion about the medical implications of a frequent angiographic finding, and highlights substantial heterogeneity among studies.
The overall estimated incidence of the primary composite outcome of all-cause death and non-fatal MI was 0.98/100 person-years. Specific incidences of all-cause death, non-fatal MI, and rehospitalization for cardiovascular causes were 0.65, 0.32, and 2.62/ 100 person-years, respectively. To provide an opportune comparison with event rates in the general population (without symptoms prompting to investigate the presence of CAD), death and MI incidences of a similarly-aged (45-64 years old) North American general population were reported to be 0.5/100 patient-years and 0.2/100 patient-years respectively. 63 In patients with angina and obstructive CAD (conventionally defined as at least one diameter stenosis >50% in one of the three main coronary arteries), incidence of death and non-fatal MI have been reported to be two to three times higher in one study. 64 In another one, in stable angina with angiographically proven CAD, the incidence of major adverse cardiac events (MACE) appears to be in the order of 4/100 patient-years, 65 therefore, at least three times higher than in our overall population. To provide other benchmark figures, the incidence of the combined endpoint of death, MI, and stroke in contemporary trials of ACSs appears to be in the order of 10/100 patient-years, 66 ,67 therefore, at least 10 times higher A B C Figure 4 Association between the primary study outcome and the prevalence of dyslipidaemia (A), hypertension (B), and diabetes (C). Each study is represented by a circle, with a localization in the graph depending on the prevalence (%) of patients with dyslipidaemia (A), hypertension (B), or diabetes (C) (on the x-axis), and the incidence of the primary outcome (on the y-axis) for each specific study. The size of the circles indicates the precision of each estimate, and the regression line is the best fit for the meta-regression model. than in the population analysed in our report. Our overall estimate of MACE-excluding stroke-in the order of 1/100 patient-years in our population appears therefore in the same bulk order of magnitude as found in low-risk primary cardiovascular disease prevention, and is usually not considered sufficiently high even for recommending aspirin treatment. 68 Indeed two previous meta-analysis have explored outcomes of patients without obstructive CAD, 4,5 but both used 'soft' inclusion criteria, enrolling extremely heterogeneous populations, with both stable and ACS patients, regardless the presence and quality of symptoms and the indication for invasive or non-invasive detection of CAD. In particular, studies enrolling also asymptomatic subjects undergoing either ICA or CCTA for suspected CAD were included in those studies. Such selection might have led to the inclusion of a large portion of asymptomatic 'healthy subjects', screened only for their cardiovascular risk profile, and to a true underestimation of the prognostic implication of angina without obstructive CAD. On the contrary, we focused on a strictly 'selected' population of symptomatic stable patients, aiming (i) to avoid the inclusion of such 'healthy' false positive subjects; and (ii) to investigate if the presence of angina in the absence of obstructive coronary stenosis, which may be supposed to be a surrogate of an underlying coronary microvascular dysfunction or of impaired epicardial coronary function, may affect prognosis. For the same purpose, we also elected to exclude studies enrolling patients with ACS, who exhibit a very different pathophysiological spectrum and a much higher incidence of MACE, which would have profoundly affected the results.
Even with these relatively strict selection criteria, however, the heterogeneity in event incidences found in the present meta-analysis suggests that differences in inclusion criteria heavily influence outcomes. A higher risk of the primary outcome was associated with the prevalence of known risk factors for CAD, such as dyslipidaemia, hypertension, and diabetes in the studied populations. Studies enrolling patients with 'some' degree of angiographically evident coronary atherosclerosis also showed a worse long-term outcomes than those with truly angiographically 'normal' coronary arteries. This is not surprising, since it is well-known that risk factors for or direct evidence of coronary atherosclerosis portend a greater risk of subsequent acute atherothrombotic events, attributed to instability of 'vulnerable' plaques, even at sites of non-critical stenoses. 69 It might similarly be argued that worse outcomes observed in such subgroups can also be ascribed to microvascular coronary dysfunction, since diabetes, hypertension, dyslipidaemia, and sub-stenotic atherosclerosis are all factors related to endothelial dysfunction and microvascular impairment. 70 In the absence of significant CAD, myocardial ischaemia may in fact derive from a functional disorder of epicardial vessels (vasospastic angina) and/or the coronary microcirculation (microvascular angina). 71 Both these forms may portend a worse prognosis, 26 justifying the need for accurate diagnostic investigations, including invasive functional testing. 72 This has been extensively reported in the Women's ischaemia Syndrome Evaluation (WISE) group studies, which showed that, among women with suspected myocardial ischaemia and 'normal' coronary arteries, an abnormal microvascular coronary function-defined as an impaired coronary flow reserve (CFR) A B Figure 5 Subgroup analysis of the primary study outcome (the combined incidence of all-cause death and myocardial infarction) by coronary atherosclerosis and myocardial ischaemia. Forest plots for estimated incidences of the primary outcome with 95% confidence interval, dividing the studies in two subgroups (yellow diamonds) according to the presence, among inclusion criteria, of less-than-obstructive coronary artery disease or the occurrence of 'entirely normal' coronary arteries at angiography (A); and of the documentation or not of myocardial ischaemia as a prerequisite (B). The blue diamond represents the overall estimated incidence with 95% confidence interval. measured after intravenous or intracoronary adenosine administration-is associated with major adverse outcomes. 73 Confirming this concept, CFR has also been shown to predict outcomes over and above the angiographic degree of CAD and clinical risk factors. 74 Unexpectedly, the subgroup of studies including only patients with objective documentation of myocardial ischaemia showed similar primary and secondary outcome incidences compared with studies where myocardial ischaemia was not a prerequisite in the enrolment criteria. However, this finding warrants caution, since the association between myocardial ischaemia and MACE might have been obscured by the presence of patients with myocardial ischaemia in the subgroup of studies where myocardial ischaemia was not routinely investigated. Furthermore, we only have information on the proportion of patients who underwent a stress test, but not on its type, quality, or results. In addition, it should be noted that non-invasive tests all suffer from suboptimal diagnostic accuracy in the detection of myocardial ischaemia, with the ExET being the most widely used first-level test (see Table 1 ), but also the one with the lowest sensitivity and specificity among other diagnostic strategies. 75 Supporting the hypothesis of heterogeneity due to the inclusion criteria based on the type of stress test used to screen myocardial ischaemia, we found that studies enrolling patients on the basis of the ExET featured much lower incidence of events than those using second-tier imaging techniques (stress echocardiography or nuclear imaging), or those documenting abnormal coronary vasomotor function. This suggests that studies enrolling patients on the basis of ExET may have been biased by the Figure 6 All-cause mortality. Forest plot with individual and overall estimated event rates with 95% confidence interval (95% CI) for all-cause death. VA-CMC registry, vasospastic angina in the Catholic Medical Center registry. Other acronyms, graph symbols, and abbreviations as in Figure 2 . inclusion of 'false positive' subjects, thus affecting the estimated incidence of MACE in the overall population, while studies enrolling on the basis of second-tier stress test were more able to reject low risk 'healthy' subjects. Likewise, patients with reportedly 'typical' angina showed a trend towards a higher incidence of the primary outcome than those with undefined angina, confirming that stricter or more lenient selection of patients in the various studies had important consequences on outcomes. Finally, we also performed a sensitivity analysis by excluding studies recruiting patients with vasospastic angina, showing that results were not affected by the inclusion of such subjects.
In conclusion, one may speculate that, across the entire spectrum of patients with angina and 'normal' coronary arteries, some may have a worse prognosis than others. At higher risk are, e.g. patients with typical angina, those with well-documented myocardial ischaemia on imaging tests, and those with objective evidence of coronary atherosclerosis. Therefore, these categories should not be overlooked, as their prognosis is probably underestimated by grouping them together with subjects having atypical angina or non-cardiac chest pain, or without documented myocardial ischaemia/coronary vasomotor dysfunction. Logical treatment is likely however, largely to be based on aggressive risk factor management, as one would do 
for high-risk primary cardiovascular prevention, 68 being all those criteria likely a hallmark of more extensive subclinical atherosclerosis and of a higher atherosclerotic burden. We also found a high incidence of hospitalization for cardiovascular causes (2.62/100 person-years), which is almost two-fold higher than that observed in a similarly aged (45-64 years) general North American population (1.5/100 person-years). 63 To provide a comparison with patients with stable obstructive CAD, hospitalization rate for unstable angina was about 4.5% person-years in the percutaneous coronary intervention group and 7.0% in the medical therapyonly group of the COURAGE trial. 76 In the REACH registry, patients with stable angina showed an incidence of hospitalization for cardiovascular causes of about 26% at 43 months median follow-up. 77 Reinforcing this concept, we also found high rates of recurrent angina and repeat coronary angiography. These findings suggest serious patient disability and important impairment in quality of life, which in turns imply high health resource consumption, as previously reported. 78 We acknowledge limitations in our analysis. First, this is a pooled analysis of non-randomized observational studies based on raw aggregate data, without access to individual-patient data. Second, we have not a relevant control group with which our findings could be compared. Third, although subgroup analyses were informative, given the substantial heterogeneity of event incidences among studies, we cannot avoid the likely overlap of patients classified as 'entirely normal coronary arteries' vs. 'less-than-obstructive' CAD, as well as overlaps between patients having properly or not properly documented myocardial ischaemia. Such interferences may have attenuated differences between subgroups. Unfortunately, for the majority of the studies here included, it is not possible to retrospectively sort-out different subgroup populations without accessing individual-patient data. However, this bias is likely only to mitigate the effect of subcritical atherosclerosis or myocardial ischaemia, which-if present-would have provided an even higher risk of adverse events than that we found in subgroup analyses, thus overall strengthening our main finding. Moreover, it should be acknowledged that, despite the large series of sensitivity analysis here performed, we cannot fully explain heterogeneity, suggesting that there are other unknown factors that may affect the findings reported by individual studies. This substantial heterogeneity also affects the reliability of the tests we performed to check for publication bias: Egger's test may be underpowered in such cases, and the trim-and-fill may inappropriately adjust for publication bias where none exists. 79 Finally, for the paucity of data provided by the study here included, we could not analyse the prognostic implications of an impaired CFR and of microvascular dysfunction, as assessed by adenosine and intracoronary acetylcholine tests.
Conclusions
Angina without obstructive CAD is quite heterogeneous and inconsistently defined among studies. In general, this condition is associated with a low incidence of death or non-fatal MI, in the order of about 1.0/100 person-years, comparable with that of the general population. However, outcomes appear to be extremely variable, and worse in patients with a higher burden of cardiovascular risk factors, 'some' coronary atherosclerosis, typical angina, and welldocumented myocardial ischaemia. Most, if not all, such factors are related to the underlying atherosclerotic burden. Finally, the high rate of re-hospitalization for cardiovascular causes suggests serious patient disability, important impairment in quality of life and imply consequent high consumption of health resources.
